Clinical Trials Logo

Non-infectious Posterior Uveitis clinical trials

View clinical trials related to Non-infectious Posterior Uveitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05523765 Active, not recruiting - Clinical trials for Non-infectious Intermediate Uveitis

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

NEPTUNE
Start date: November 14, 2022
Phase: Phase 2
Study type: Interventional

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).

NCT ID: NCT01526889 Completed - Clinical trials for Non-infectious Intermediate Uveitis

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

Start date: December 20, 2012
Phase: Phase 2
Study type: Interventional

This was a multi-center, randomized, active-controlled, open-label study. Approximately 24 patients with active, non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy were enrolled. Safety, efficacy, and PK assessments occurred at scheduled visits over a 12-week period. Low-molecular-weight non-steroidal immunosuppressive medications were allowed up to the baseline day as long as the dose had not changed in the 3 weeks prior to baseline, except for corticosteroid doses for which might have changed. Patients responding to treatment were offered up to 6 months of extended treatment. Assessments for safety included laboratory safety tests, ECGs, physical exams, ocular exams, vital signs and the monitoring of adverse events. Study participation varied from a minimum of 3 months to a maximum of 9 months.